Interim open-label study results suggest higher dapivirine vaginal ring use, lower HIV risk

(Burness) Interim data from a large open-label study of the monthly dapivirine ring have found increased product use compared to a previous Phase III study. In addition, modeling data suggest that women's HIV-1 risk in the open-label study, known as DREAM, was reduced by more than half. Developed by the nonprofit International Partnership for Microbicides (IPM), the monthly ring slowly releases the antiretroviral drug dapivirine and is currently under regulatory review.